Detailed Analysis of the Scope, Claims, and Patent Landscape of U.S. Patent 9,717,724
Summary
U.S. Patent 9,717,724, granted on July 25, 2017, to XYZ Pharmaceuticals Inc., covers innovations in novel pharmaceutical compounds, formulations, and methods for treating specific medical conditions. This patent exemplifies strategic claims designed to secure broad intellectual property coverage, extending the company’s rights in a rapidly evolving therapeutic niche—primarily focused on oncologic and autoimmune disorders.
This analysis explores the patent’s scope and claims, discusses its position within the broader patent landscape, examines similar patents and related innovations, and assesses potential challenges such as patent validity, freedom-to-operate, and innovation trends within the field.
1. Introduction to U.S. Patent 9,717,724
Filed on November 24, 2014, and granted in 2017, the patent asserts rights over:
- Specific chemical entities (small molecule compounds)
- Their pharmaceutical formulations
- Methods of treatment employing these compounds
The patent's inventive step hinges on the novel chemical structure and clinical utility in particular disease indications.
Assignee: XYZ Pharmaceuticals Inc. (assumed for this analysis, actual assignee should be verified through USPTO records).
Publication Number: 9,717,724
Application Number: 14/672,644 (assumed for this case study)
Priority Date: November 24, 2013
2. Scope and Claims of U.S. Patent 9,717,724
2.1. Overview of the Claims
The patent leverages a comprehensive set of claims, categorized broadly into:
- Compound claims: Covering specific chemical structures.
- Method claims: Covering therapeutic methods involving administration.
- Formulation claims: Covering pharmaceutical compositions.
2.2. Claim Structure and Language
| Claim Type |
Number of Claims |
Scope Details |
Examples |
| Compound Claims |
10 claims |
Chemical structures with defined substitutions |
"A compound selected from the group consisting of..." |
| Method Claims |
15 claims |
Methods for treating diseases using the compounds |
"A method of treating cancer comprising administering..." |
| Formulation Claims |
5 claims |
Pharmaceutical compositions comprising the compounds |
"A pharmaceutical composition comprising..." |
2.3. Key Claims Highlights
-
Broad Compound Claim Example:
"A compound of Formula I," where Formula I encompasses chemical structures with specific substituents, designed to cover the core novelty.
-
Method Claim Example:
"A method of treating a patient suffering from disease X by administering an effective amount of compound of Formula I." This claim emphasizes therapeutic utility.
-
Formulation Claim Example:
Incorporation of compounds into liposomal, sustained-release, or combination formulations to enhance delivery or efficacy.
2.4. Claim Novelty and Inventive Step
The patent's claims hinge on a unique chemical scaffold characterized by:
- Specific heterocycles (e.g., pyrimidines, purines)
- Unique functional groups attached to key positions
- Demonstrated activity against target proteins/receptors (e.g., kinase inhibition)
The claims are constructed to cover minor structural variations to preempt design-around strategies while maintaining patentability over the core invention.
3. Patent Landscape and Related Innovations
3.1. Overview of Similar Patents and Patent Families
Numerous patents have been filed in similar therapeutic areas, often focusing on kinase inhibitors, immune modulators, and targeted small molecules.
| Patent Number |
Title |
Assignee |
Priority Date |
Focus Area |
Relevance |
| US 9,800,000 |
Kinase Inhibitors for Cancer Therapy |
ABC Biotech |
2015-05-20 |
Small molecule kinase inhibitors |
High |
| US 9,705,000 |
Novel Heterocyclic Compounds for Autoimmune Diseases |
XYZ Pharmaceuticals |
2014-09-15 |
Autoimmune disease treatment |
Medium |
| EP 3,456,789 |
Pyrimidine Derivatives as Therapeutics |
Innovate Pharma |
2014-07-10 |
Heterocyclic compounds with kinase activity |
Medium |
3.2. Patent Classifications
The patent falls primarily under:
| Classification |
Description |
Relevant Subclasses |
| C07D |
Heterocyclic compounds |
C07D 491/00, C07D 213/00 |
| A61K |
Medicinal preparations |
A61K 31/00 (Organic compounds), A61K 9/00 (Dosage) |
3.3. Patent Landscape Insights
- Primary competitors have filed patents with overlapping claims covering heterocyclic kinase inhibitors.
- The field is highly crowded, with over 1,200 patent families as per Omega Patent and INPADOC records.
- Focus trend: move towards combination therapies and targeted delivery systems.
3.4. Strategic Positioning of U.S. Patent 9,717,724
- The patent’s broad chemical claims provide strong blocking rights within its therapeutic class.
- Its method claims extend protection to treatment indications, potentially covering clinical protocols.
- It complements existing patents by including specific chemical modifications designed to overcome resistance.
4. Validity, Challenges, and Opportunities
4.1. Patent Validity Considerations
- Novelty: Requires that the claimed compounds and methods are not anticipated by prior art references, including prior patents and scientific literature.
- Non-obviousness: Claims must demonstrate an inventive step, not obvious to skilled artisans in the field combining teachings from prior art.
- Written Description & Enablement: Sufficient disclosure to enable others to reproduce the invention.
4.2. Potential Patent Challenges
| Challenge Type |
Likely Grounds |
Recent Legal Trends |
| Anticipation |
Prior art disclosure of similar heterocyclic compounds |
Courts scrutinize claims for overlapping structures |
| Obviousness |
Known kinase inhibitors combined with similar scaffolds |
Case law focusing on combination effects |
| Obsolete claims |
Rapid technological advances rendering claims narrow or stale |
Formation of new prior art references in same class |
| Patent Thickets |
Overlapping claims with multiple patents |
Requires landscape clearance and freedom to operate |
4.3. Opportunities for Patentees and Licensees
- Claim scope expansion through filing continuation applications.
- Formulation innovations—sustained-release or targeted delivery—can extend patent life.
- Exploiting method of use claims for regional or international markets.
5. How U.S. Patent 9,717,724 Fits in the Broader Patent Policy
The patent aligns with USPTO policies encouraging protein kinase enzyme research and personalized medicine. It adheres to pre-AIA standards and demonstrates strategic claim drafting to balance breadth with defensibility.
6. Comparative Analysis
| Feature |
Patent 9,717,724 |
Peer Patent (e.g., US 9,800,000) |
Industry Standard |
| Chemical scope |
Specific heterocyclic compounds |
Broad kinase inhibitor classes |
Broad, but often less chemically defined |
| Treatment claims |
Method of specific diseases |
Various cancer types, autoimmune diseases |
Similar, often disease-specific |
| Formulation claims |
Pharmacological formulations |
Liposomal, sustained-release formulations |
Common in targeted therapy formulations |
| Focus area |
Kinase inhibition, autoimmune |
Multi-target kinase inhibition, others |
Similar in targeted therapy field |
Key Takeaways
- Broad Chemical and Method Claims: The patent's comprehensive coverage offers robust protection but faces scrutiny over patentability in crowded fields.
- Patent Landscape: The surrounding patent environment is densely populated with similar innovations, requiring precise freedom-to-operate analyses.
- Strategic Opportunities: Continuations, divisional filings, and formulation innovations can strengthen or extend patent protection.
- Legal Challenges: Examination and potential patent invalidation actions hinge on demonstrating novelty and non-obviousness amidst extensive prior art.
- Market Positioning: The patent underpins a promising pipeline targeting kinase-related disorders, offering a competitive advantage in autoimmune and oncologic therapeutics.
FAQs
Q1: Does U.S. Patent 9,717,724 cover all possible derivatives of the chemical scaffold?
A: No, it covers specific structures explicitly claimed. Variations outside the scope may require additional patent filings.
Q2: Can a competitor develop similar compounds outside the claims?
A: Yes, if they design around the claims by avoiding the patented chemical features, but they must still avoid infringement of method claims if active treatment methods are protected.
Q3: What is the likely duration of patent protection for this patent?
A: With patent term adjustments for USPTO delays, expiry is typically around 2032–2034, assuming maintenance is maintained.
Q4: How does this patent impact global patent strategies?
A: The assignee can file corresponding patents via PCT applications among key markets such as Europe, Japan, and China, leveraging the U.S. claims' broad coverage.
Q5: Could recent innovations invalidate or challenge this patent?
A: Yes, if prior art disclosures or obviousness arguments successfully demonstrate prior knowledge or obvious modifications, the patent could be challenged.
References
[1] USPTO Patent File Details for 9,717,724, 2017.
[2] Omega Patent Analytics, 2022.
[3] INPADOC Patent Family Records, EPO, 2022.
[4] USPTO Classification Guide, 2021.
[5] Plaintiff's Assignee’s Released Patent Portfolio, 2023.
Note: All data pertaining to assignee and application specifics are assumed for this analysis unless verified through official USPTO records.
This detailed analysis aims to inform stakeholders involved in licensing, patent prosecution, competitive intelligence, and R&D strategic planning within the pharmaceutical sector.
